fluoxetine + yohimbine

Fluoxetine + yohimbine is a combination of two small molecule drugs used experimentally in the management of major depressive disorder. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin levels by inhibiting its reuptake, thereby exerting antidepressant effects. Yohimbine is an alpha-2 adrenergic receptor antagonist that enhances noradrenergic and serotonergic neurotransmission by blocking presynaptic inhibition of norepinephrine release. The combination has been studied for its potential to accelerate and potentiate the antidepressant response compared to fluoxetine alone, likely due to synergistic effects on monoaminergic systems[1][5]. Yohimbine has also been investigated as a treatment for fluoxetine-induced sexual dysfunction[2].